.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP57_GlecaprevirAndPibrentasv.GlecaprevirAndPibrentasv .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP57_GlecaprevirAndPibrentasv.GlecaprevirAndPibrentasv| name: | GlecaprevirAndPibrentasvir |
| ATC code: | J05AP57 | route: | oral |
| n-compartments | 2 |
Glecaprevir and pibrentasvir is a fixed-dose combination antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection in adults and children. It acts as a direct-acting antiviral by inhibiting HCV NS3/4A protease (glecaprevir) and NS5A (pibrentasvir). The combination is approved worldwide for treating all major HCV genotypes.
Pharmacokinetic data in healthy adults and HCV-infected patients; mixed-sex adult population. Parameters are for steady-state after multiple oral doses of 300 mg glecaprevir / 120 mg pibrentasvir once daily.
Lin, CW, et al., & Liu, W (2017). Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects. Journal of clinical pharmacology 57(12) 1616–1624. DOI:10.1002/jcph.959 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28800195